General Mills echoes FedEx with a warning about weaker demand

General Mills echoes FedEx with a warning about weaker demand


Limited Edition holiday breakfast cereal, Christmas Crunch in holiday shapes, Target store, Queens, New York. (Photo by: Lindsey Nicholson/UCG/Universal Images Group via Getty Images)

Lindsey Nicholson | Getty Images

Two big companies weighed in on persistent demand woes this week.

General Mills, which reported earnings Wednesday morning, said tepid demand and pricing pressures are compounding problems for the Dunkaroos and Bisquick maker. That echoed what FedEx said in its report after the bell Tuesday.

FedEx shares fell 10% on Wednesday, on pace for its worst day in 15 months, while General Mills’ stock slipped about 2%.

And, just like FedEx, General Mills trimmed its full-year sales outlook. With two quarters remaining in the Cheerios producer’s fiscal year, the company now sees revenue down 1% to flat, compared with previous guidance of a 3% to 4% increase.

General Mills is also cutting the high end of its earnings guidance due to the lower demand forecast. It expects “a slower volume recovery in fiscal 2024, reflecting a more cautious consumer economic outlook.”

While General Mills reported its eighth consecutive quarterly earnings beat, revenue came up well short of estimates: $5.14 billion vs. $5.35 billion expected, according to LSEG, formerly known as Refinitiv. It was General Mills’ biggest revenue miss in eight years.

CEO Jeff Harmening said the company saw “a slower-than-expected volume recovery in the second quarter amid a continued challenging consumer landscape.”

Organic sales growth was an eyesore, unexpectedly contracting 2% versus Street estimates of 3.1% positive growth. Every business segment saw disappointing sales, from consumer food to pet food, from domestic to international.

Volumes fell 4% overall – led by a 5% drop in North America retail volumes. Pricing increases continued to decelerate, contributing just 3 percentage points to sales in the latest quarter.

The company has also been boosting promotions.

“We’re seeing consumers continue to display stronger-than-anticipated value-seeking behaviors across our key markets, and this dynamic is delaying volume recovery in our categories,” Harmening said in a call with analysts.



Source

FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More
Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war
Business

Toyota, Hyundai and Chinese automakers expected to be most impacted by Iran war

Toyota Motor Corp. vehicles bound for shipment at the Port of Nagoya in Tokai, Aichi Prefecture, Japan, on Tuesday, April 29, 2025. Toru Hanai | Bloomberg | Getty Images DETROIT — Toyota Motor, Hyundai Motor and Chinese automakers such as Chery face the most potential impact of non-domestic automakers from the U.S.-Israel war with Iran, […]

Read More